REGULATED PRESS RELEASE published on 07/11/2024 at 07:01, 3 months 7 days ago Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study
REGULATED PRESS RELEASE published on 07/11/2024 at 07:01, 3 months 7 days ago Biophytis obtient l’autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l’obésité Biophytis obtient l'autorisation IND de la FDA pour lancer l'étude OBA de phase 2 dans l'obésité avec BIO101 (20-hydroxyecdysone), visant à améliorer la force musculaire. Le professeur Marc-André Cornier dirigera l'étude multicentrique aux Etats-Unis Biophytis BIO101 Obésité Autorisation IND Étude OBA
BRIEF published on 07/01/2024 at 07:05, 3 months 17 days ago Biophytis Presents Promising Phase 2-3 COVA Study Results on Severe Covid-19 at WCID in Paris Biophytis COVID-19 Clinical Trials COVA Study Infectious Diseases
BRIEF published on 07/01/2024 at 07:05, 3 months 17 days ago Biophytis présente les résultats de l'étude COVA de phase 2-3 sur le Covid-19 au WCID à Paris Biophytis COVID-19 Résultats Cliniques Phase 2-3 Infectiologie
PRESS RELEASE published on 07/01/2024 at 07:00, 3 months 17 days ago Biophytis a présenté les résultats de l'étude COVA de phase 2-3 dans les formes sévères de Covid-19 lors du WCID à Paris Biophytis présente les résultats de l'étude COVA de phase 2-3 sur le traitement du Covid-19 lors du WCID à Paris. Les résultats sont positifs avec réduction significative des risques Biophytis COVID-19 COVA Résultats Phase 2-3
PRESS RELEASE published on 07/01/2024 at 07:00, 3 months 17 days ago Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis presents positive results from Phase 2-3 COVA study for severe Covid-19 at WCID Paris. Bio101 shows significant efficacy and safety in reducing risk of respiratory failure and death Biophytis COVID-19 Positive Results Phase 2-3 COVA Study Respiratory Failure
REGULATED PRESS RELEASE published on 07/01/2024 at 07:00, 3 months 17 days ago Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis presented positive results of its Phase 2-3 COVA study for severe Covid-19 at WCID in Paris, showing reduction in respiratory failure and death rates Biophytis COVID-19 Positive Results Phase 2-3 COVA Study
REGULATED PRESS RELEASE published on 07/01/2024 at 07:00, 3 months 17 days ago Biophy(s a présenté les résultats de l'étude COVA de phase 2-3 dans les formes sévères de Covid-19 lors du WCID à Paris Biophytis présente les résultats de l'étude COVA de phase 2-3 sur les formes sévères de Covid-19 lors du WCID à Paris. Des résultats positifs de réduction du risque de défaillance respiratoire et de mortalité sont révélés Biophytis COVID-19 Résultats Positifs Étude COVA Réduction Du Risque De Mortalité
BRIEF published on 06/25/2024 at 23:05, 3 months 22 days ago Biophytis Approves All Resolutions at General Meeting Shareholders Biophytis General Meeting Resolutions
BRIEF published on 06/25/2024 at 23:05, 3 months 22 days ago Résultats de l'Assemblée Générale Mixte de Biophytis du 24 juin 2024 Biophytis Assemblée Générale Resolutions Quorum Vote
Published on 10/18/2024 at 09:40, 2 hours 34 minutes ago Opti Digital Breaks Down the Biggest AdTech Trends in 2025
Published on 10/18/2024 at 08:00, 4 hours 14 minutes ago First Day of Dealings on AIM and Completion of Fundraise
Published on 10/18/2024 at 08:00, 4 hours 14 minutes ago FE Battery Metals Corp. Announces Closing of Private Placement
Published on 10/18/2024 at 00:00, 12 hours 14 minutes ago River City Bank Reports Net Income of $16.2 Million for the Third Quarter of 2024, Net Income of $52.1 Million Year to Date, and a Quarterly Cash Dividend
Published on 10/17/2024 at 23:00, 13 hours 14 minutes ago GameHost Announces Regular Monthly Dividend for October
Published on 10/18/2024 at 12:07, 6 minutes ago 13 February 2025: Capital Markets Day and Presentation of the Results for the 2024 Financial Year
Published on 10/18/2024 at 12:05, 8 minutes ago 13 February 2025: Capital Markets Day and Presentation of the Results for the 2024 Financial Year
Published on 10/18/2024 at 10:52, 1 hour 21 minutes ago The 15th Turkish-Arab Economic Forum took place at the Four Seasons Bosphorus Hotel in Istanbul, with the participation of prominent figures and representatives from many countries.
Published on 10/18/2024 at 10:52, 1 hour 21 minutes ago Le 15e Forum économique turco-arabe s'est tenu à l'hôtel Four Seasons Bosphorus d'Istanbul, avec la participation de personnalités et de représentants de nombreux pays.
Published on 10/18/2024 at 08:00, 4 hours 14 minutes ago NFL BIOSCIENCES : L’ÉQUIPE DIRIGEANTE PRÉPARE LES PROCHAINES ÉTAPES DU DÉVELOPPEMENT
Published on 10/18/2024 at 08:00, 4 hours 14 minutes ago NFL BIOSCIENCES: LEADERSHIP TEAM PREPARING THE NEXT STAGES IN ITS DEVELOPMENT
Published on 10/17/2024 at 17:45, 18 hours 29 minutes ago COGELEC : Chiffre d’affaires du 3e trimestre 2024 : 17,4 M€ (+ 13,1 %).